NCT07721142招募中4 期
Integrated Clinical Study of Traditional Chinese and Western Medicine for the Treatment of Refractory Rheumatoid Arthritis Using Renowned Traditional Chinese Medicines
Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2025年10月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- the ACR20 response rate at week 12
研究概览
简要总结
To evaluate the efficacy and safety of Kunxian Capsule combined with Methotrexate and Tofacitinib in the treatment of difficult-to-treat rheumatoid arthritis through a multicenter, randomized, double-blind, placebo-controlled clinical trial, and to identify the therapeutic advantages of integrated Chinese and Western medicine for optimizing the clinical strategy of D2T RA.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must meet all of the following criteria to be enrolled in this study:
- •Fully understand the purpose and requirements of the trial, voluntarily participate by signing written informed consent, and be willing and able to complete the study procedures, including medication administration and follow-up assessments;
- •Male patients aged ≥50 years with no fertility requirements, or postmenopausal female patients, younger than 70 years;
- •Patients diagnosed with rheumatoid arthritis (RA) according to the 1987 revised criteria of the American College of Rheumatology (ACR), or the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria;
- •Patients with RA of the "Wind-Damp Bi obstruction" pattern according to traditional Chinese medicine (TCM), defined as:
- •Primary symptoms: joint pain and swelling with a wandering nature; joint pain and swelling with intermittent occurrence.
- •Secondary symptoms: aversion to wind, or spontaneous sweating; headache; heaviness of the limbs.
- •Tongue and pulse: pale-red tongue with thin white coating, slippery or floating pulse.Diagnosis requires at least 2 primary symptoms, or 1 primary symptom plus 2 secondary symptoms, in combination with tongue and pulse findings.
- •Patients with confirmed moderate to severe active RA at screening, defined as ≥6 tender joints (TJC, based on 68-joint count) and ≥6 swollen joints (SJC, based on 66-joint count), with erythrocyte sedimentation rate (ESR) >28 mm/h or C-reactive protein (CRP) >10 mg/L, and DAS28-CRP >3.2;
- •Prior inadequate response (DAS28-ESR >3.2) to at least two disease-modifying antirheumatic drug (DMARD) regimens (excluding methotrexate + JAK inhibitor + Kunxian capsule), each administered for at least 12 weeks.
排除标准
- •Subjects meeting any of the following conditions will not be eligible for enrollment:
- •Suspected or confirmed allergy to the investigational drug (including excipients or drugs of the same class), or any other severe allergic disease (excluding RA itself) that, in the investigator's judgment, may compromise subject safety;
- •Presence of inflammatory diseases other than RA, including but not limited to psoriatic arthritis, ankylosing spondylitis, or systemic lupus erythematosus;
- •Severe, progressive, or uncontrolled diseases of the kidneys, liver, blood, gastrointestinal tract, endocrine system, lungs, heart, nervous system, psychiatric conditions, or brain; history of venous thromboembolism, diverticulitis, significantly abnormal or poorly controlled blood lipids;
- •History of lymphoproliferative disorders, or current or past malignancy;
- •Meeting any of the following criteria for tuberculosis screening, which require exclusion:
- •History of active tuberculosis;
- •Recent close contact with patients with active tuberculosis;
- •Signs or symptoms of active tuberculosis based on medical history and physical examination;
- •Chest CT scan within 3 months prior to enrollment showing evidence of active pulmonary tuberculosis;
- •Positive interferon-gamma release assay (IGRA) within 6 weeks prior to enrollment;
- •Presence or history of active infections, including:
- •Receipt of systemic anti-infective therapy within 4 weeks prior to randomization;
- •Pharyngalgia, nasal congestion, acute upper respiratory tract infection, or systemic acute infection within 2 weeks prior to randomization;
- •Recurrent, chronic, or other active infections at screening that, in the investigator's judgment, may increase subject risk;
- •History of recurrent herpes zoster, disseminated herpes zoster, or disseminated herpes simplex, or history of herpes zoster or herpes simplex within 2 months prior to randomization;
- •Positive hepatitis B surface antigen (HBsAg) and/or HBV DNA >50 IU/mL (or >500 copies/mL) at screening; positive hepatitis C virus antibody, human immunodeficiency virus (HIV) antibody, or Treponema pallidum antibody;
- •Receipt of, or planned receipt of, live or attenuated vaccines within 3 months prior to the first dose of study medication, during the study, or within 6 months after the last study dose;
- •Pregnant, breastfeeding, planning pregnancy, or planning fatherhood during the study or within 6 months after the last dose; females or males with fertility requirements;
- •Clinically significant abnormalities on 12-lead ECG at screening that may increase subject risk, in the investigator's judgment;
- •Any other disease at screening that may interfere with study assessments;
- •Laboratory abnormalities at screening, defined as:
- •Hemoglobin <100.0 g/L in males, or <90.0 g/L in females;
- •White blood cell (WBC) count <4.0 × 10⁹/L;
- •Neutrophil count <1.5 × 10⁹/L;
- •Platelet (PLT) count <100 × 10⁹/L;
- •Lymphocyte count <0.5 × 10⁹/L;
- •Aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBIL), or serum creatinine (Scr) above the upper limit of normal;
- •Hematology, liver function, or renal function abnormalities that, in combination with medical history and/or additional examinations, are deemed clinically significant by the investigator;
- •Prior use of any of the following drugs or treatments:
- •Strong opioids within 1 week prior to randomization;
- •Any JAK inhibitor within 2 weeks prior to randomization;
- •Nonsteroidal anti-inflammatory drugs (NSAIDs) at the time of randomization with dosage adjustments within 2 weeks prior;
- •Prednisone or equivalent corticosteroid >10 mg/day at randomization; or ≤10 mg/day with dosage adjustment within 4 weeks prior to randomization;
- •Intra-articular, intramuscular, intravenous, trigger-point, bursal, or tendon-sheath corticosteroid injections within 4 weeks prior to randomization or during the study;
- •Concurrent participation in another drug clinical trial;
- •Any clinically significant abnormalities in clinical or laboratory examinations, or any other reason deemed inappropriate for study participation by the investigator.
结局指标
主要结局
the ACR20 response rate at week 12
时间窗: To compare the ACR20 response rate at week 12 between the Kunxian Capsule combined with methotrexate (MTX) and JAK inhibitor (JAKi) group and the methotrexate (MTX) plus JAK inhibitor (JAKi) group.
次要结局
未报告次要终点
研究者
Dongyi He
doctor
Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Traditional Chinese Medicine Hand-Foot Soak for Chemotherapy-Induced Peripheral Neuropathy and Hand-Foot SyndromeNCT07375446Peking University Third Hospital300
招募中
不适用
Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis (AS): A Cohort Study Protocol Focusing on Spondyloarthritis Research Consortium of Canada (SPARCC) Scoring SystemAnkylosing Spondylitis (AS)Integrated Traditional Chinese and Western MedicineNCT07509775China-Japan Friendship Hospital210
招募中
不适用
Efficacy and Safety of Qishen Yiqi Dropping Pills in Patients With Severe Pulmonary HypertensionNCT07604805Guangdong Provincial People's Hospital120
尚未招募
3 期
Testing Herbal Pretreatment For IVF Success In Women With Low Ovarian ReserveNCT07347340Peking Union Medical College Hospital348
尚未招募
2 期
A Pilot Trial of Chinese Medicine for Patients With Dialytic HypotensionNCT07425262Chang Gung Memorial Hospital100